Grella D K, Castellino F J
Department of Chemistry and Biochemistry, University of Notre Dame, IN 46556, USA.
Blood. 1997 Mar 1;89(5):1585-9.
To directly determine whether the mechanism of activation of human plasminogen (HPg) by staphylokinase (Sak) required formation of an active complex of Sak and HPg, recombinant (r) variants of HPg were examined that allowed dissection of the steps involved in this activation. The rate of activation of wild-type (wt) r-HPg by equimolar levels of Sak was enhanced when small amounts of human plasmin (HPm) were included, suggesting that a Sak-HPm complex was a more effective plasminogen activator than a putative Sak-HPg complex. Incubation of equimolar Sak with a cleavage site resistant mutant of HPg (r-[R581 A]HPg) did not result in generation of amidolytic activity of the complex, in contrast to a similar experiment with streptokinase (SK) in place of Sak, where substantial amidolytic activity was generated. This result supplies evidence that an active complex of Sak and HPg does not form, as is the case with SK. Another mutant, r-[D646 E]HPg, which, upon activation, would lead to a form of HPm defective in enzymatic activity, is also not converted to its two-chain form by Sak, but is converted to the inactive two-chain form by urokinase, a direct plasminogen activator, and by equimolar complexes of SK or Sak with wtr-HPm. This shows that the active site of HPm is the functional plasminogen activator entity in the Sak-HPm complex. These results show that the mechanism of activation of HPg by Sak proceeds in a distinctly different manner than the similar activation by SK. Although SK does not require the presence of HPm for this activation, a necessary condition for the activation by Sak is formation of a small amount of HPm generated via another activation pathway. These different mechanisms have significant implications in production of the fibrinolytic state by these two indirect bacterial plasminogen activators.
为了直接确定葡萄球菌激酶(Sak)激活人纤溶酶原(HPg)的机制是否需要形成Sak与HPg的活性复合物,我们检测了HPg的重组(r)变体,以便剖析该激活过程中涉及的步骤。当加入少量人纤溶酶(HPm)时,等摩尔水平的Sak对野生型(wt)r-HPg的激活速率会提高,这表明Sak-HPm复合物比假定的Sak-HPg复合物是更有效的纤溶酶原激活剂。与用链激酶(SK)代替Sak进行的类似实验不同,等摩尔的Sak与HPg的裂解位点抗性突变体(r-[R581A]HPg)孵育不会导致复合物产生酰胺水解活性,在用SK进行的类似实验中会产生大量酰胺水解活性。该结果提供了证据,表明Sak和HPg不会像SK那样形成活性复合物。另一个突变体r-[D646E]HPg在激活后会产生一种酶活性有缺陷的HPm形式,它也不会被Sak转化为其二链形式,但会被直接纤溶酶原激活剂尿激酶以及SK或Sak与wt r-HPm的等摩尔复合物转化为无活性的二链形式。这表明HPm的活性位点是Sak-HPm复合物中的功能性纤溶酶原激活剂实体。这些结果表明,Sak激活HPg的机制与SK的类似激活过程明显不同。虽然SK进行这种激活不需要HPm的存在,但Sak激活的一个必要条件是通过另一条激活途径产生少量HPm。这些不同的机制对这两种间接细菌纤溶酶原激活剂产生纤溶状态具有重要意义。